Evidence map›Paper›PMID 40676307›Full record

ReviewArchives of microbiology2025

Unveiling the potential of antimicrobial peptides to combat Mycobacterium tuberculosis.

Saurabh Gupta, Rasanpreet Kaur, Anshu Upadhyay, Jitendra Singh, Bhuvnesh Prasad Sharma, Jagdip Singh Sohal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Peptide-Based Strategies AgainstPharmaceuticals (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Saurabh Gupta *Department of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Chaumuhan, Mathura, Uttar Pradesh, 281406, India. saurabhbiotech12@gmail.com.
Rasanpreet Kaur *Department of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Chaumuhan, Mathura, Uttar Pradesh, 281406, India.
Anshu UpadhyayDepartment of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Chaumuhan, Mathura, Uttar Pradesh, 281406, India.
Jitendra SinghDepartment of Translational Medicine, All India Institute of Medical Sciences Bhopal, Saket Nagar, Bhopal, Madhya Pradesh, 462020, India.
Bhuvnesh Prasad SharmaDepartment of Biotechnology, Bhagwant University, Sikar Rd, Ajmer, 305004, Rajasthan, India.
Jagdip Singh SohalDepartment of Research and Development, Chandigarh University, Mohali, Punjab, 140413, India.

Funding

Council of Science and Technology, Uttar Pradesh 3066
6 · The paper itself

Abstract

Tuberculosis (TB) is a severe disease that causes considerably high morbidity and mortality in low- and middle-income developing nations. The causative agent of TB, Mycobacterium tuberculosis (Mtb), has evolved medication resistance, which has hampered the treatment of TB. The need for new anti-TB medications has been driven by the growth of multi-drug-resistant (MDR) mycobacterial strains, resistance to current medicines, and a rising financial burden. In this context, antimycobacterial peptides obtained from diverse sources, including human cells, bacteria, mycobacteriophages, plants, and animals, may serve as potential antituberculosis agents. This is because the majority of these peptides exhibit dual benefits, namely, bactericidal activity against Mtb and immunoregulatory properties. AMPs are strong contenders for alternative therapeutic alternatives or adjuvants in TB treatment because some of the peptides have the added benefit of interacting synergistically with antituberculosis drugs as well, improving their efficacy. This review highlights AMPs' potential modes of action, benefits, and drawbacks compared to traditional antibiotics, as well as how to solve usage-related issues to increase their therapeutic potential. We also discuss the difficulties in translating benchside research to the bedside, assess the state of the development pipeline, and examine the anticipated socioeconomic effects worldwide.

Indexed as

Antimicrobial PeptidesAntitubercular AgentsMycobacterium tuberculosisTuberculosisAnimalsHumansAntimicrobial PeptidesAntitubercular AgentsAntimicrobial peptidesAntimicrobial resistanceImmuno-regulatoryMycobacteriaTuberculosis

Identifiers

PMID40676307

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.